CardieX files 510(k) for dual blood pressure, arterial health monitor
Australian-listed health technology company CardieX has filed a pre-510(k) application with the US Food and Drug Administration for its dual blood pressure and artery health monitor.
Dubbed CONNEQT Pulse, the health monitor features CardieX’s FDA-cleared SphygmoCor technology, which measures central blood pressure to measure multiple arterial health indicators such as arterial stiffness, pulse pressure, and key indicators of vascular health in the brain, heart, kidneys, and other important ones Organs.
The Pulse will be the first integration of SphygmoCor into a blood pressure monitor, the company said.
In addition, the device can be integrated into the mobile CONNEQT app for consumers. It can also be connected to the CONNEQT doctor portal to enable remote patient monitoring and management.
Both the patient app and physician portal allow for customization and prioritization of the parameters collected by Pulse, providing personalized insights into specific health conditions.
“For example, a patient at risk for Alzheimer’s disease may want to prioritize viewing central pulse pressure and arterial stiffness, while a patient wishing to treat hypertension may want to prioritize both central and brachial blood pressure readings,” the company said.
4DMedical expands nationwide partnership with I-MED
Health technology company 4DMedical and radiology service provider I-MED Radiology Network have expanded their partnership across the country.
I-MED, which operates a network of more than 250 clinics across Australia, previously secured a commercial deal to deploy 4DMedical’s lung imaging technology at some of its clinics in Berwick, Brisbane, Wagga Wagga, Launceston and Albury.
These clinics have used 4DMedical’s diagnostic support and disease monitoring tool called XV Lung Ventilation Analysis Software to diagnose diseases such as long-lived COVID-19, asthma, COPD and silicosis.
The new three-year contract aims to make the XV imaging technology available to other select i-MED clinics across the country. Several clinics in Sydney, Melbourne, Adelaide and Perth are said to be ready for launch.
“[The] Expanding our proven capabilities across the country means many more people will have access to the latest technology in respiratory imaging,” said Dr. Andreas Fouras, CEO and Managing Director of 4DMedical.
As part of the agreement, both companies also agreed to establish a Lung Center of Excellence utilizing 4DMedical’s XV technology “to enable world-class research and development activities to advance diagnostic imaging” in Australia.
The Institute of Functional Neuroscience launches neuroplasticity intervention software
The Institute of Functional Neuroscience in Australia has launched its neuroplasticity intervention application in partnership with US life science software company MetaCell.
The software, called IFN Neurologic, is used to perform restorative neuroplasticity procedures. Neuroplasticity refers to the brain’s ability to modify, change, and adapt in response to experience.
According to a press release, the application will help clinicians better care for patients with neurological disorders and offer treatments in the field of functional neuroscience.
“With this new software, which requires no installation and is accessible from any web browser in the world, we now have the ability to quickly scale our diagnostic processes and reach more patients around the world at the touch of a button,” said IFN Director Dr . Randy Beck.
Introduced as a pilot project last year, IFN Neurologic is now available to clinicians and patients worldwide as part of a partner program that also includes a comprehensive training program and other required hardware and software.